Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech, Inc. (NASDAQ:KRYS) has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug KB408 for the treatment of alpha-1 antitrypsin deficiency (AATD).
September 05, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's Orphan Drug Designation for Krystal Biotech's KB408 could potentially boost the company's stock in the short term.
The FDA's Orphan Drug Designation is a significant regulatory milestone that could potentially lead to faster approval and market exclusivity for KB408. This could increase the company's revenues and profitability, which would likely have a positive impact on its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100